U.S., Aug. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07119918) titled 'PCSK9 Inhibitor for Intracranial Atherosclerotic Symptomatic Stenosis' on Aug. 06.

Brief Summary: An investigator-initiated, prospective, multicenter, randomized, double-blind, placebo-controlled trial comparing the 1-year incidence of stroke in patients with AIS or TIA within 7 days who are treated with either placebo or Recaticimab.

Study Start Date: Sept. 01

Study Type: INTERVENTIONAL

Condition: Symptomatic Intracranial Atherosclerotic Stenosis

Intervention: DRUG: Recaticimab

Recaticimab 300mg subcutaneous Q8W for 1 year.

DRUG: Placebo

Matched placebo subcutaneous Q8W for 1 year.

Recruitment Status: NOT_YET_RECRUITING ...